Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181427 · ClinicalTrials.gov registry record · Phase 1
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
NCT01181427 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 137 participants.
The verdict
NCT01181427, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
Study Summary
Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.
Interventions
- DRUG Placebo
- PROCEDURE Blood Sample Collection
- DRUG ABT-267
- DRUG Cytochrome P450 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01181427
The ClinicalTrials.gov registry entry for NCT01181427 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01181427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01181427 about?
NCT01181427 is a clinical study titled "Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects". Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.
What is the current status of trial NCT01181427?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01181427?
The interventions under investigation include: Placebo (DRUG), Blood Sample Collection (PROCEDURE), ABT-267 (DRUG), Cytochrome P450 inhibitor (DRUG).
Who is sponsoring clinical trial NCT01181427?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.